Peer-reviewed veterinary case report
Dog with brain tumor showed improvement after nimustine treatment
By Tagawa, Michihito et al.·Published in Open veterinary journal·2024·Faculty of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Therapeutic effect of nimustine in a dog with intracranial histiocytic sarcoma.
- Species:
- dog
Plain-English summary
A 9-year-old Welsh Corgi was brought in with severe weakness in all four legs, which had been worsening for two months. An MRI showed a tumor in the dog's brain, and after a biopsy, the dog was treated with a chemotherapy drug called nimustine. The treatment led to some improvement in the dog's symptoms and a decrease in tumor size for a while. Unfortunately, the tumor grew back later, and despite additional treatment, the dog passed away about six months after starting therapy.
People also search for: dog brain tumor treatment · Welsh Corgi quadriplegia · nimustine for dogs
Abstract
BACKGROUND: Intracranial histiocytic sarcoma (HS) is uncommon in dogs, and no standard treatment has yet been defined for this disease. Herein, we describe a case of intracranial HS that responded favorably to nimustine treatment. CASE DESCRIPTION: A 9-year-old, castrated Welsh Corgi Pembroke presented with a 2-month history of quadriplegia. Intracranial disease was suspected on neurological examination, and magnetic resonance imaging (MRI) revealed a contrast-enhanced mass in the left frontal lobe. Following tissue biopsy, the patient received intravenous nimustine (ACNU) treatment. The patient's neurological symptoms partially improved, and a reduction in tumor volume was observed on MRI on day 99. After three administrations of ACNU, tumor regrowth was confirmed on day 124, and temozolomide was subsequently administered. The patient subsequently showed no major changes in clinical symptoms, but subsequently died suddenly on day 195. CONCLUSION: In this case, administration of ACNU provided temporary symptom improvement and tumor reduction. Therefore, ACNU monotherapy may be a therapeutic option for canine intracranial HS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39545189/